When anti-CD20 was combined with immunomodulatory reagents, only anti-OX40 provided a modest benefit with a median survival of 45.5 days (Figure 1A), with the other reagents providing small, non-statistically significant improvements in tumor control. The gene discussed is TNFRSF4; the disease is neoplasm.